Home » Stocks » INO

Inovio Pharmaceuticals, Inc. (INO)

Stock Price: $6.67 USD -0.18 (-2.63%)
Updated May 10, 2021 4:00 PM EDT - Market closed
Pre-market: $5.86 -0.81 (-12.14%) May 11, 9:26 AM
Market Cap 1.44B
Revenue (ttm) 6.46M
Net Income (ttm) -188.27M
Shares Out 202.41M
EPS (ttm) -1.07
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 10
Last Price $6.67
Previous Close $6.85
Change ($) -0.18
Change (%) -2.63%
Day's Open 7.01
Day's Range 6.61 - 7.20
Day's Volume 16,053,518
52-Week Range 6.23 - 33.79

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

PLYMOUTH MEETING, Pa., May 10, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from i...

17 hours ago - PRNewsWire

PLYMOUTH MEETING, Pa., May 10, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectiou...

1 day ago - PRNewsWire

PLYMOUTH MEETING, Pa., May 4, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious...

1 week ago - PRNewsWire

Inovio (INO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 week ago - Zacks Investment Research

Analysts believe these underperformers could nearly double over the next 12 months.

Other stocks mentioned: ICPT, SRPT
1 week ago - The Motley Fool

It might be able to, although it won't be easy.

1 week ago - The Motley Fool

PLYMOUTH MEETING, Pa., April 27, 2021 /PRNewswire/ -- INOVIO (NASDAQ: INO) announced today that first quarter 2021 financial results will be released after the market close on May 10, 2021.

2 weeks ago - PRNewsWire

These tiny stocks could pack big-time return potential, if analysts are correct.

Other stocks mentioned: EVER, HRVSF, JUSHF, VXRT
2 weeks ago - The Motley Fool

Everything may depend on an early-stage program.

2 weeks ago - The Motley Fool

There's real value in being a first-mover.

Other stocks mentioned: MRNA
2 weeks ago - The Motley Fool

Inovio Pharmaceuticals said Friday the Department of Defense pulled its funding for final-phase testing of the company's Covid vaccine and device, prompting INO stock to collapse. The post Inovio Stock ...

2 weeks ago - Investors Business Daily

The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.

2 weeks ago - The Motley Fool

Novavax, Inc. (NASDAQ: NVAX), Inovio Pharmaceuticals, Inc. (NASDAQ: INO) and Protara Therapeutics, Inc. (NASDAQ: TARA) are among the biotech movers Friday. Novavax Moves On Mid-stage Malaria Vaccine Dat...

Other stocks mentioned: NVAX, TARA
2 weeks ago - Benzinga

Inovio Pharmaceuticals Inc (NASDAQ: INO) shares dived in the premarket in reaction to the company's plans for a predominantly ex-U.S. Phase 3 trial for its COVID-19 vaccine candidate, INO-4800. Given th...

2 weeks ago - Benzinga

PLYMOUTH MEETING, Pa., April 23, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infecti...

2 weeks ago - PRNewsWire

It's all about the ultimate coronavirus vaccine.

2 weeks ago - The Motley Fool

PPD, Inc. (NASDAQ: PPD), Immunic, Inc. (NASDAQ: IMUX), Inovio Pharmaceuticals, Inc. (NASDAQ: INO) and CureVac N.V. (NASDAQ: CVAC) are among the healthcare movers on Thursday.

Other stocks mentioned: CVAC, IMUX
3 weeks ago - Benzinga

PLYMOUTH MEETING, Pa., April 15, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from...

3 weeks ago - PRNewsWire

Investors need to pay close attention to Inovio (INO) stock based on the movements in the options market lately.

4 weeks ago - Zacks Investment Research

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF continues its investigatio...

1 month ago - Business Wire

It has to do with game-changing technology.

1 month ago - The Motley Fool

Inovio has thrown its hat into the coronavirus vaccine ring with big biopharma names like Moderna, Johnson & Johnson and Pfizer. But INO stock is volatile on its vaccine news.

1 month ago - Investors Business Daily

We believe that Inovio Pharmaceuticals , a biotechnology company focused on synthetic DNA products for treating cancers and infectious diseases, is a good buying opportunity at the present time. INO sto...

1 month ago - Forbes

Inovio Pharmaceuticals, Inc. (NASDAQ: INO), which has fallen behind in the COVID-19 vaccine race, has much to offer beyond a coronavirus vaccine, according to a BofA Securities analyst.  The Inovio Anal...

1 month ago - Benzinga

With the trading day about halfway over, the broad markets had pulled back slightly.

Other stocks mentioned: DKNG, GSK, LUV, NFLX, ALXN, BURL, MDB ...
1 month ago - 24/7 Wall Street

Let's look at what some of the smartest investors are saying.

Other stocks mentioned: VXRT
1 month ago - The Motley Fool

Why? They're focusing on one of the biggest coronavirus problems.

Other stocks mentioned: GRTS, NVAX
1 month ago - The Motley Fool

Although these stocks are popular with the Reddit community, they're bad news.

Other stocks mentioned: BLNK, GME, SNDL
1 month ago - The Motley Fool

PLYMOUTH MEETING, Pa., March 15, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infecti...

1 month ago - PRNewsWire

The biotech could be a winner over the long run but faces some significant challenges.

1 month ago - The Motley Fool

There was one big wrinkle with the biotech's study.

2 months ago - The Motley Fool

INO stock is poised to fall further as the chances of a vaccine approval fall and its competitors widen their lead The post Sell Inovio While You Still Can appeared first on InvestorPlace. More From Inv...

2 months ago - InvestorPlace

The stock price of Inovio Pharmaceuticals, a biotechnology company focused on synthetic DNA products for treating cancers and infectious diseases, has seen a large 27% drop over the last ten trading day...

2 months ago - Forbes

PLYMOUTH MEETING, Pa., March 3, 2021 /PRNewswire/ -- Geneos Therapeutics, a clinical stage company focused on the development of tumor neoantigen targeted personalized immunotherapies for cancer, announ...

2 months ago - PRNewsWire

Investors still appear to have doubts about two of the biotech's lead candidates.

2 months ago - The Motley Fool

Better-than-expected top- and bottom-line results weren't enough.

2 months ago - The Motley Fool

These are the stocks posting the largest moves after the bell on Monday, March 1.

Other stocks mentioned: NVAX, ROKU, ZM
2 months ago - CNBC

Inovio Pharmaceuticals Inc (NASDAQ: INO) shares are lower in after-hours trading in reaction to multiple catalysts. REVEAL 1 Study Reveals Mixed Results In Cervical Dysplasia: Inovio said a pivotal REVE...

2 months ago - Benzinga

Shares of Inovio Pharmaceuticals (NASDAQ:INO) moved higher  in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share were up 63.16% over the past year to ($0.1...

2 months ago - Benzinga

PLYMOUTH MEETING, Pa., March 1, 2021 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from...

2 months ago - PRNewsWire

On Monday, March 01, Inovio Pharmaceuticals (NASDAQ:INO) will release its latest earnings report. Benzinga's report can help you figure out the ins and outs of the earnings release.

2 months ago - Benzinga

Inovio (INO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

2 months ago - Zacks Investment Research

Qiagen NV (NYSE: QGEN) and Inovio Pharmaceuticals Inc (NASDAQ: INO) expanded their partnership with a new master collaboration agreement to develop liquid biopsy-based companion diagnostic products usin...

Other stocks mentioned: QGEN
2 months ago - Benzinga

PLYMOUTH MEETING, Pa. and GERMANTOWN, Md. and HILDEN, Germany, Feb. 24, 2021 /PRNewswire/ -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and INOVIO Pharmaceuticals (NASDAQ: INO) today announced a...

2 months ago - PRNewsWire

Inovio (INO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

On Inovio's (INO) fourth-quarter earnings call, investor focus will be on updates on the company's progress with the development of its COVID-19 vaccine candidate, INO-4800.

2 months ago - Zacks Investment Research

This straggler in the vaccine race is still facing some struggles -- but there are a couple of bright spots.

2 months ago - The Motley Fool

Inovio Pharmaceuticals (INO) closed the most recent trading day at $13.84, moving -0.93% from the previous trading session.

2 months ago - Zacks Investment Research

The choice isn't easy, but simplicity may be the answer.

Other stocks mentioned: VXRT
2 months ago - The Motley Fool

Shares of coronavirus vaccine developer Inovio Pharmaceuticals Inc (NASDAQ: INO) were surging Friday after a vote of confidence from the Street.  Bullish Analyst, Fund Stake Prop Up Stock: Oppenheimer a...

2 months ago - Benzinga

About INO

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon optimized plasmids that have ability to help break the immune system's tolerance of cancerous or infected cells and facilitate cross-strain protection against unmatched and matched pathogen variants. The company is involved in conducting an... [Read more...]

Industry
Biotechnology
IPO Date
Feb 12, 1998
CEO
Jong Kim
Employees
262
Stock Exchange
NASDAQ
Ticker Symbol
INO
Full Company Profile

Financial Performance

In 2020, INO's revenue was $7.41 million, an increase of 80.24% compared to the previous year's $4.11 million. Losses were -$166.41 million, 39.4% more than in 2019.

Financial Statements

Analyst Forecasts

According to 8 analysts, the average rating for INO stock is "Hold." The 12-month stock price forecast is 14.63, which is an increase of 119.34% from the latest price.

Price Target
$14.63
(119.34% upside)
Analyst Consensus: Hold